SBIR and STTR Success Story for
Selexys Pharmaceuticals Corporation

(Information Posted/Updated on 01/09/2013)

Selexys Pharmaceuticals Corporation
840 Research Parkway
Suite 510
Oklahoma City, OK  73104

Contact:    Scott Rollins, Ph.D.
Phone:      405-319-8198
Fax:          405-319-8197
Web Site:

Project Title:  Development of an Anti-PSGL-1 Antibody to Treat Crohn’s Disease
Related Award(s):  1R44DK085845-01A1 and 4R44DK085845-02
Technology Developed:
Selexys Pharmaceuticals is developing a humanized anti-PSGL-1 antibody for the treatment of Crohn’s Disease.

Key Words:  inflammation, PSGL-1, antibodies, P-selectin, adhesion, Crohn's Disease.
Uses of Technology/Products/Service:
Preclinical studies in mouse models of spontaneous ileitis (SAMP1) demonstrated a profound and sustained therapeutic effect of an anti-PSGL-1 for treating Crohn’s Disease. Selexys humanized anti-PSGL-1 antibody is a pan-selectin and chemokine inhibitory antibody that has application in multiple inflammatory and thrombotic disease indications.

Benefit to Company:
NIDDK SBIR funding has impacted this program in several positive ways. The funding supported preclinical studies in cynomolgus monkey to determine safety and the pharmacokinetics of an anti-PSGL-1 antibody. The funding will support planned Phase I/II clinical studies in Crohn’s Disease patients to assess safety and efficacy. Potential investors and partners view funding awards from the NIH as an independent assessment of the merits of the program. This award supports the company’s efforts to raise sufficient capital to meet major clinical development milestones. The SBIR program seeds important development work and demonstrates the value of private/public financing to move new drugs to approval and commercial launch.

How Product Was Commercialized:
The product being developed requires FDA approval for commercial launch.

Other Comments Related to Company's Success Story:
Selexys management team has a solid track record in the development, FDA approval and launch of biologics for indications with major unmet medical needs. Selexys recently closed a $25M private equity Series A round of financing that in part supports the aims of this program.